MCRC
Clinical trials for MCRC explained in plain language.
Never miss a new study
Get alerted when new MCRC trials appear
Sign up with your email to follow new studies for MCRC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New biosimilar aims to offer cheaper option for colorectal cancer
Disease control Not yet recruitingThis Phase 1 trial tests a new drug called HLX05-N, which is a biosimilar (a copy) of the cancer drug Erbitux, in 387 people with metastatic colorectal cancer. Participants will receive either HLX05-N or Erbitux (from the US or EU) along with standard chemotherapy. The study aims…
Matched conditions: MCRC
Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hard-to-treat colon cancer: combo attack with immunotherapy and radiation
Disease control Not yet recruitingThis phase 2 study tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) and targeted radiation to a standard targeted therapy (fruquintinib) can help people with metastatic colorectal cancer that has spread to a few spots. The trial will enroll 60 adults who …
Matched conditions: MCRC
Phase: PHASE2 • Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for advanced colon cancer: drug duo targets tumors
Disease control Not yet recruitingThis study tests a new drug combination (SHR-1811 plus bevacizumab) as a second-line treatment for people with metastatic colorectal cancer that has worsened after initial therapy. About 80 adults aged 18-75 will participate. The goal is to see if the combo shrinks tumors and del…
Matched conditions: MCRC
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC